Q-omics provides the consensus-scored MOCS1P1 profile across patient tissues and cancer cell-line models. MOCS1P1 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in ESCA. Among the 18 cancer types available for tumor–normal comparison, MOCS1P1 is differentially expressed in 6, with the highest sampling consensus in HNSC. Additionally, MOCS1P1 RNA expression shows 6,678 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight ESCA, HNSC, and STAD as cancer lineages where MOCS1P1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MOCS1P1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MOCS1P1 survival associations across molecular data types. MOCS1P1 RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MOCS1P1 RNA expression–survival associations across cancer types. High MOCS1P1 expression shows unfavorable associations in COAD, PAAD, THCA, LUSC and HNSC, but favorable associations in ESCA. The ESCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify ESCA as the clearest survival context for MOCS1P1 RNA expression.
This table summarizes MOCS1P1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for MOCS1P1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MOCS1P1 shows lower tumor expression in BRCA and KIRP and higher tumor expression in HNSC, LUAD, LIHC and KICH. The HNSC box plot shows higher MOCS1P1 RNA expression in tumor versus normal tissue (log2 FC = +0.072, t-test p = .001).
This table shows molecular features associated with MOCS1P1 in patient tissues and cancer cell lines. In patient samples, MOCS1P1 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
